APA (7th ed.) Citation

(2018). Orphan designation: Amatuximab for the treatment of malignant mesothelioma, 16 Jan 2014, Positive (EU/3/13/1222). Chemical Business NewsBase (UK).

Chicago Style (17th ed.) Citation

"Orphan Designation: Amatuximab for the Treatment of Malignant Mesothelioma, 16 Jan 2014, Positive (EU/3/13/1222)." Chemical Business NewsBase (UK) 2018.

MLA (8th ed.) Citation

"Orphan Designation: Amatuximab for the Treatment of Malignant Mesothelioma, 16 Jan 2014, Positive (EU/3/13/1222)." Chemical Business NewsBase (UK), 2018.

Warning: These citations may not always be 100% accurate.
Visit our Citation Styles guide for help on properly citing sources.